EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Catastrophic Health Expenditure and Health‐Related Quality of Life Impairment in Severe Haemophilia A: A Patient‐Level Cost‐of‐Illness Study From India

M Joseph John, Mridul Makkar, Himanshu Aggarwal, Damanpreet Singh, Soumya Ohja, Diksha Sarwan, Gaurav Jyani, Shankar Prinja

Haemophilia · 2026-11 · 32 (6) · 1444-1454

DOI: 10.1111/hae.70323 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Introduction Severe haemophilia A (sHA) is associated with disability, and financial burden. Even with government provided or humanitarian‐aid‐supported on‐demand therapy, households may remain vulnerable to catastrophic health expenditure (CHE). Aim To estimate the patient‐level costs and economic burden of sHA and to assess CHE under multiple thresholds. Methods In this cross‐sectional study, costs were estimated from a patient/household perspective. Clotting‐factor concentrate (CFC) costs were excluded from the base case because factor VIII was provided free through government and/or humanitarian‐aid‐supported mechanisms. Costs were standardized to 2025 Indian Rupees using Consumer Price Index (CPI) adjustments (US$ (₹90 = US$1)). CHE was assessed at 10% and 25% of total household expenditure and 40% of household capacity to pay. Results The median annual patient‐level cost per patient, excluding CFCs, was ₹73,919 (US$821). CHE occurred in 63% of households at the 10% threshold and in 44% at the 40% capacity‐to‐pay threshold. Distance > 50 km From the treatment centre (aOR 6.62) and hospitalization history (aOR 10.60) were associated With CHE. Median cost per bleeding episode, excluding factor costs, was ₹4,468 (US$50; IQR ₹8,311 [US$92]). HRQoL utilities were modestly reduced and weakly correlated With costs, suggesting a financial–disability utility paradox. Sensitivity analysis identified clotting‐factor price as the dominant cost driver Conclusion SHA imposes substantial financial burden Despite free factor provision. Reliance on on‐demand therapy may contribute to recurrent bleeding, hospitalizations, and CHE, whereas long‐term replacement strategies may reduce complications and financial toxicity. Prospective comparative studies are needed in resource‐constrained settings Clinical Trial Registration This study was not a clinical trial and, therefore, did not require clinical trial registration.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →